Last reviewed · How we verify
NCT04741841
Effect of Probiotics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
NA trial testing GutMagnific™ H. in Myalgic Encephalomyelitis in 74 participants. Completed in 30 June 2021.
30 March 2021
Quick facts
| Lead sponsor | ImmuneBiotech Medical Sweden AB |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 74 |
| Start date | 30 March 2020 |
| Primary completion | 30 March 2021 |
| Estimated completion | 30 June 2021 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- GutMagnific™ H.
- GutMagnific™ L.
- Placebo
Conditions studied
- Myalgic Encephalomyelitis — all drugs for Myalgic Encephalomyelitis →
- Chronic Fatigue Syndrome — all drugs for Chronic Fatigue Syndrome →
Sponsor
ImmuneBiotech Medical Sweden AB
Who can join
18 and older, any sex, with Myalgic Encephalomyelitis or Chronic Fatigue Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a neurological disease. Currently there is no effective treatment for ME/CFS due to unclear etiology of the disease. The aim of this randomized double-blind placebo-control clinical trial is to study the efficacy of the probiotic food supplement "GutMagnific™" in ME/CFS and comorbid gastrointestinal complications. The outcome of the study will be assessed based on the data from different self-reporting questionnaires and intestinal microbial flora analysis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The microbiome in post-acute infection syndrome (PAIS).
Guo C, Yi B, Wu J, Lu J. · · 2023 · cited 7× · PMID 37602232 · DOI 10.1016/j.csbj.2023.08.002
Verify or expand the search:
- PubMed search for NCT04741841
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myalgic Encephalomyelitis
Currently open trials in the same condition.
- NCT05741112 — The Long COVID-19 Wearable Device Study · NA · recruiting
- NCT05236465 — A 3-day Course for CFS/ME · NA · recruiting
- NCT05167227 — Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing · NA · active not recruiting
- NCT04542161 — Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04741841 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ImmuneBiotech Medical Sweden AB
- Last refreshed: 14 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04741841.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing